Related Experiment Videos
Targeted, non-viral gene delivery for cancer gene therapy
1Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 109, Houston, Texas 77030, USA. rcristia@notes.mdacc.tmc.edu
Abstract:
The ability to mediate targeted and specific delivery of therapeutics to cancer cells remains one of the most important hurdles in effectively treating cancer. This aspect also remains as one of the greatest limitations of gene therapy as well. Targeted vectors based on the use of DNA-binding agents attached to cell specific ligands or "molecular conjugates" were created with the goal of over-coming this hurdle. Since being conceived, many different ligands have been utilized as molecular conjugates, targeting the resulting Protein/DNA polyplex to cells efficiently in vitro while mediating limited delivery in vivo. This limited delivery is due to many reasons such as the need to identify non-viral agents that can aide in escaping endosome entrapment as well as decreasing the complexity that has evolved in the creation of these "synthetic viruses". This review will discuss the current status and the future of molecular conjugates as targeting vectors as well as the positive and negative attributes of this vector in relation to other viral and non-viral vectors that are currently used in many gene therapy strategies.
Insights
Molecular conjugates offer targeted cancer therapy by linking DNA-binding agents to cell-specific ligands. While effective in vitro, in vivo delivery challenges persist, necessitating further research for improved gene therapy strategies.
Area of Science:
- Biomedical Engineering
- Molecular Biology
- Cancer Therapeutics
Background:
- Targeted delivery of therapeutics to cancer cells is a significant challenge in cancer treatment and gene therapy.
- Molecular conjugates, utilizing DNA-binding agents and cell-specific ligands, were developed to overcome these delivery hurdles.
Purpose of the Study:
- To review the current status and future potential of molecular conjugates as targeting vectors in gene therapy.
- To discuss the advantages and disadvantages of molecular conjugates compared to other viral and non-viral vectors.
Main Methods:
- Review of existing literature on molecular conjugates for targeted gene delivery.
- Analysis of various ligands used in molecular conjugate design.
- Comparison of in vitro and in vivo delivery efficiencies.
Main Results:
- Molecular conjugates demonstrate efficient in vitro targeting but face limited in vivo delivery.
- Challenges include endosomal escape and vector complexity.
- Various ligands have been explored, with varying degrees of success.
Conclusions:
- Molecular conjugates hold promise for targeted cancer therapy and gene delivery.
- Overcoming in vivo limitations, such as endosomal entrapment, is crucial for clinical translation.
- Further development is needed to optimize these synthetic vectors for effective gene therapy strategies.